Lisinopril (Zestril): An Overview

What is Lisinopril and Its Uses?

Lisinopril, marketed under the brand name Zestril, is a prescription medication classified as an angiotensin-converting enzyme (ACE) inhibitor. It is primarily used to lower blood pressure in adults and children over six years of age who are diagnosed with hypertension. Additionally, it is utilized in the treatment of congestive heart failure and may be administered to stable patients within 24 hours following a heart attack, potentially reducing the risk of mortality.

Cost-Effectiveness of Lisinopril

One of the advantages of Lisinopril and other ACE inhibitors is their relative affordability compared to alternative blood pressure medications. This affordability can be particularly beneficial for those without insurance coverage.

Discovery and Development of Lisinopril

History of Lisinopril

Lisinopril is a long-lasting analog of the ACE inhibitor enalapril. Its once-daily dosing schedule, in contrast to the multiple doses required for enalapril, may enhance patient compliance by simplifying medication regimens. Lisinopril received approval for use in the United States in 1988.

Mechanism of Action

How Lisinopril Works

Lisinopril functions by inhibiting the angiotensin-converting enzyme (ACE), which catalyzes the formation of angiotensin II, a compound that constricts blood vessels. By reducing angiotensin II levels, Lisinopril increases bradykinin levels, leading to vasodilation. This dilation, along with decreased aldosterone levels—resulting in increased sodium and water excretion—contributes to lower blood volume and, consequently, reduced blood pressure. The lowered blood pressure may also decrease the likelihood of adverse cardiovascular events, such as heart attacks and strokes.

Common Side Effects

Potential Side Effects of Lisinopril

A frequently reported side effect of Lisinopril is a dry cough, which is believed to be linked to elevated bradykinin levels. Other common side effects include headaches, angioedema, chest pain, nausea, and dizziness. Lisinopril may also result in hypotension, prompting physicians to start patients on a low dose and monitor them closely during the initial treatment phase.

Risks Associated with Lisinopril

Lisinopril can increase the risk of hyperkalemia, characterized by elevated potassium levels in the blood, due to decreased aldosterone leading to reduced potassium excretion. Patients should inform their healthcare providers about any potassium supplements or potassium-based salt substitutes they are using. Some studies suggest that Lisinopril and other ACE inhibitors may elevate the risk of hypoglycemia in individuals with diabetes.

Important Considerations

This article is for informational purposes only and is not intended to provide medical advice, diagnose, or promote specific treatments for any condition.

References

1. Rx Professional (2020 July 14). RxList. Retrieved 2021 March 1, from https://www.rxlist.com/zestril-drug.htm#description
2. John. M. Eisenberg Center for Clinical Decisions and Communications Science (2010). “ACE Inhibitors” and “ARBs” to protect your heart?: A guide for patients being treated for stable coronary heart disease. Comparative Effectiveness Review Summary Guides for Consumers [Internet]. Retrieved 2021 March 1, from https://www.ncbi.nlm.nih.gov/books/NBK51219/
3. Lopez, E., et al (2020 December 2). Lisinopril. StatPearls [Internet]. Retrieved 2021 March 1, from https://www.ncbi.nlm.nih.gov/books/NBK482230/
4. Access Data: Drugs at FDA [pdf]. (2014). Food and Drug Administration. Retrieved 2021 March 1, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019777s064lbl.pdf
5. Klabunde, R.E., PhD. (2017 November 17). Cardiovascular Pharmacology Concepts. Retrieved 2021 March 1, from https://cvpharmacology.com/vasodilator/ACE
6. Goa, K.L., Balfour, J.A., Zuanetti, G. (1996). Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 52(4): 564-588. Doi: 10.2165/00003495-199652040-00011
7. Vue, M.H., PharmD, Setter, S.M., PharmD, CDE, CGP (2011). Drug-induced glucose alterations part 1: Drug-Induced Hypoglycemia (Pharmacy and Therapeutics). Diabetes Spectrum 24(3): 171-177.